Cargando…

Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy

Research on immune checkpoint blockade therapy has made great progress in cancer immunotherapy, but the number of patients who benefit from this therapy remains limited. In this study, we examined the effects of monotherapy with systemic low-dose resiquimod, a synthesized TLR7 agonist, and examined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishii, Naoto, Tachinami, Hidetake, Kondo, Yuta, Xia, Yulong, Kashima, Yoshihisa, Ohno, Tatsukuni, Nagai, Shigenori, Li, Lixin, Lau, Walter, Harada, Hiroyuki, Azuma, Miyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862579/ https://www.ncbi.nlm.nih.gov/pubmed/29568358 http://dx.doi.org/10.18632/oncotarget.24327

Ejemplares similares

Overexpression of PD‐L1 in gingival basal keratinocytes reduces periodontal inflammation in a ligature‐induced periodontitis model
por: Wongtim, Keeratika, et al.
Publicado: (2021)

Overload of the Temporomandibular Joints Accumulates γδ T Cells in a Mouse Model of Rheumatoid Arthritis: A Morphological and Histological Evaluation
por: Nagai, Kohei, et al.
Publicado: (2022)

Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer
por: Azuma, Takeshi, et al.
Publicado: (2020)

Progress and Current Status in Hajdu-Cheney Syndrome with Focus on Novel Genetic Research
por: Aida, Natsuko, et al.
Publicado: (2022)

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
por: Gonzalez, Caleb, et al.
Publicado: (2023)

Treatment of severe micrognathia in an adult with distraction osteogenesis: A case report
por: Sekido, Katsuhisa, et al.
Publicado: (2023)

Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma
por: Asai-Tajiri, Yukari, et al.
Publicado: (2014)

DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects
por: Ota, Yosuke, et al.
Publicado: (2023)

The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
por: Koido, Shigeo, et al.
Publicado: (2013)

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
por: Dowling, David J., et al.
Publicado: (2022)

Combinations using checkpoint blockade to overcome resistance
por: Morganti, Stefania, et al.
Publicado: (2020)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
por: Ribas, Antoni, et al.
Publicado: (2021)

Durable complete response to immunotherapy with anti‐PD‐1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report
por: Sekido, Katsuhisa, et al.
Publicado: (2021)

Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
por: Sekido, Katsuhisa, et al.
Publicado: (2023)

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
por: Zheng, Wenxin, et al.
Publicado: (2016)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: Farias, A., et al.
Publicado: (2021)

Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
por: Kawanabe-Matsuda, Hirotaka, et al.
Publicado: (2022)

Central mucoepidermoid carcinoma of the maxilla developing from a calcifying odontogenic cyst: A rare case report
por: Isshiki‐Murakami, Megumi, et al.
Publicado: (2021)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Blockade of TLR2 and TLR4 Attenuates Inflammatory Response and Parasite Load in Cutaneous Leishmaniasis
por: Carneiro, Pedro Paulo, et al.
Publicado: (2021)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease
por: Yu, Xiaocong, et al.
Publicado: (2013)

Trial watch: TLR3 agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

OMV Vaccines and the Role of TLR Agonists in Immune Response
por: Mancini, Francesca, et al.
Publicado: (2020)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

TLR Agonist Therapy of Metastatic Breast Cancer in Mice
por: Klinman, Dennis M., et al.
Publicado: (2023)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

TLR3 and TLR9 Agonists Improve Postexposure Vaccination Efficacy of Live Smallpox Vaccines
por: Israely, Tomer, et al.
Publicado: (2014)

Conventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report
por: Kimura, Yutaro, et al.
Publicado: (2017)

Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists
por: Lacerte, Patricia, et al.
Publicado: (2016)

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Development of N-Acetylated Dipalmitoyl-S-Glyceryl Cysteine Analogs as Efficient TLR2/TLR6 Agonists
por: Zhou, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lc4aefm0sua1hqh022408j65qh